Suppr超能文献

HIV 感染和抗逆转录病毒治疗会增加近端肾小管功能异常的风险。

Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.

机构信息

Services de Maladies Infectieuses et Tropicales and COREVIH, Hôpital Pellegrin, CHU de Bordeaux, Université Bordeaux Segalen, Bordeaux, France.

出版信息

Kidney Int. 2011 Aug;80(3):302-9. doi: 10.1038/ki.2011.124. Epub 2011 May 4.

Abstract

Abnormal kidney function is common in the course of human immunodeficiency virus (HIV) infection. Here, we performed a cross-sectional analysis using 399 patients within the Aquitaine cohort (a hospital-based cohort of HIV-1-infected patients receiving routine clinical management) to estimate the prevalence of proximal renal tubular dysfunction (PRTD) associated with HIV infection. These patients did not differ statistically by sociodemographics, median age, years since HIV diagnosis, AIDS stage, or median CD4 cell count from the entire 3080 patient cohort. Antiretroviral therapy was received by 352 patients, with 256 given tenofovir (TDF); 325 had undetectable HIV plasma viral load, and 26 were diagnosed with PRTD. In multivariate analysis, significant independent associations were found between PRTD and age (odds ratio (OR) 1.28 per 5-year increase), atazanavir (OR 1.28 per year of exposure), and TDF (OR 1.23 per year) treatment. Among patients having received TDF-containing regimens over a 5-year period, PRTD remained significantly associated with TDF exposure when treatment was ongoing (OR 5.22) or had been discontinued (OR 11.49). Thus, cumulative exposure to TDF and/or atazanavir was associated with an increased risk of PRTD, with concern about its reversibility in patients with HIV.

摘要

肾功能异常在人类免疫缺陷病毒(HIV)感染过程中很常见。在这里,我们对 Aquitaine 队列中的 399 名患者进行了横断面分析(这是一个基于医院的 HIV-1 感染患者队列,接受常规临床管理),以估计与 HIV 感染相关的近端肾小管功能障碍(PRTD)的患病率。这些患者在社会人口统计学、中位年龄、HIV 诊断后年限、艾滋病分期或中位 CD4 细胞计数方面与整个 3080 名患者队列没有统计学差异。352 名患者接受了抗逆转录病毒治疗,其中 256 名患者接受了替诺福韦(TDF)治疗;325 名患者的 HIV 血浆病毒载量无法检测到,26 名患者被诊断为 PRTD。多变量分析发现,PRTD 与年龄(每增加 5 岁,比值比 [OR] 为 1.28)、阿扎那韦(暴露每年,OR 为 1.28)和 TDF(暴露每年,OR 为 1.23)治疗呈显著独立关联。在接受 TDF 治疗的患者中,在 5 年内接受 TDF 治疗的患者中,PRTD 与 TDF 暴露仍显著相关,无论治疗是否持续(OR 5.22)或已停止(OR 11.49)。因此,TDF 和/或阿扎那韦的累积暴露与 PRTD 的风险增加相关,这引起了对 HIV 患者中其可逆性的关注。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验